EPIZON

Serial Number 86984319
Registration 5692098
702

Registration Progress

Application Filed
Nov 17, 2015
Under Examination
Dec 27, 2016
Approved for Publication
Nov 1, 2016
Published for Opposition
Nov 1, 2016
Registered
Mar 5, 2019

Attorney Assistance

Section 8 (6-Year) Declaration Due (Based on registration date 2019-03-05)
Due: Mar 05, 2025 Overdue

Trademark Image

EPIZON

Basic Information

Serial Number
86984319
Registration Number
5692098
Filing Date
November 17, 2015
Registration Date
March 5, 2019
Published for Opposition
November 1, 2016
Drawing Code
3

Status Summary

Current Status
Active
Status Code
702
Status Date
Jan 31, 2025
Registration
Registered
Classes
005

Rights Holder

Epizon Pharma, Inc.

03
Address
16 Lunar Drive
Woodbridge, CT 06525

Ownership History

Epizon Pharma, Inc.

Original Applicant
03
Woodbridge, CT

Epizon Pharma, Inc.

Owner at Publication
03
Woodbridge, CT

Epizon Pharma, Inc.

Original Registrant
03
Woodbridge, CT

Legal Representation

Attorney
Alexander P. Montgomery

USPTO Deadlines

Next Deadline
1334 days remaining
Section 8 & 9 (10-Year) Renewal Due (Based on registration date 2019-03-05)
Due Date
March 05, 2029
Grace Period Ends
September 05, 2029

Application History

49 events
Date Code Type Description
Jan 31, 2025 NA85 E NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
Jan 31, 2025 C15A O REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
Jan 31, 2025 APRE A CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Sep 13, 2024 E815 I TEAS SECTION 8 & 15 RECEIVED
Mar 5, 2024 REM1 E COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Mar 5, 2019 R.PR A REGISTERED-PRINCIPAL REGISTER
Jan 31, 2019 SUNA E NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Jan 30, 2019 CNPR P ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Jan 4, 2019 MDSC E NOTICE OF DESIGN SEARCH CODE E-MAILED
Jan 3, 2019 SUPC I STATEMENT OF USE PROCESSING COMPLETE
Jan 3, 2019 DPCC D DIVISIONAL PROCESSING COMPLETE
Dec 19, 2018 IUAF S USE AMENDMENT FILED
Dec 19, 2018 DRRR I DIVISIONAL REQUEST RECEIVED
Dec 19, 2018 ERTD I TEAS REQUEST TO DIVIDE RECEIVED
Dec 19, 2018 EISU I TEAS STATEMENT OF USE RECEIVED
Nov 29, 2018 EWAF I TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
May 29, 2018 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 25, 2018 EX3G S SOU EXTENSION 3 GRANTED
May 25, 2018 EXT3 S SOU EXTENSION 3 FILED
May 25, 2018 EEXT I SOU TEAS EXTENSION RECEIVED
Nov 29, 2017 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Nov 27, 2017 EX2G S SOU EXTENSION 2 GRANTED
Nov 27, 2017 EXT2 S SOU EXTENSION 2 FILED
Nov 27, 2017 EEXT I SOU TEAS EXTENSION RECEIVED
Jun 2, 2017 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 31, 2017 EX1G S SOU EXTENSION 1 GRANTED
May 31, 2017 EXT1 S SOU EXTENSION 1 FILED
May 31, 2017 EEXT I SOU TEAS EXTENSION RECEIVED
May 31, 2017 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED
May 5, 2017 CHAN I APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
May 1, 2017 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL
Apr 11, 2017 EWAF I TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Dec 27, 2016 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Nov 1, 2016 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Nov 1, 2016 PUBO A PUBLISHED FOR OPPOSITION
Oct 12, 2016 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Sep 26, 2016 PREV O LAW OFFICE PUBLICATION REVIEW COMPLETED
Sep 20, 2016 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER
Sep 1, 2016 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 1, 2016 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 25, 2016 ALIE A ASSIGNED TO LIE
Aug 19, 2016 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 11, 2016 GNRT F NON-FINAL ACTION E-MAILED
Mar 11, 2016 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED
Mar 11, 2016 CNRT R NON-FINAL ACTION WRITTEN
Mar 9, 2016 DOCK D ASSIGNED TO EXAMINER
Nov 21, 2015 MDSC E NOTICE OF DESIGN SEARCH CODE E-MAILED
Nov 20, 2015 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 20, 2015 NWAP I NEW APPLICATION ENTERED

Detailed Classifications

Class 005
pharmaceutical preparations for the treatment of vascular disease, cardiovascular disease, heart disease, osteoporosis, bone disease, renal disease, kidney disease, autoimmune disease, atherosclerosis, excluding devices or drug systems for the delivery of pharmaceuticals for the treatment of allergic reactions, anaphylaxis, or asthma and pharmaceuticals for the treatment of allergic reaction, anaphylaxis or asthma
First Use Anywhere: Jul 30, 2018
First Use in Commerce: Jul 30, 2018

Additional Information

Design Mark
The mark consists of the word "EPIZON" featuring a benzene ring as the "O".
Color Claim
Color is not claimed as a feature of the mark.

Classification

International Classes
005